Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

[1]  D. White,et al.  Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells , 2010, Leukemia.

[2]  J. Goldman.  Chronic myeloid leukemia: reversing the chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.

[4]  J. Melo,et al.  Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy , 2010, Leukemia.

[5]  H. Kantarjian,et al.  Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history , 2010, Leukemia.

[6]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Giles,et al.  Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia , 2009, Leukemia.

[8]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[9]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[10]  Susan O'Brien,et al.  Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. , 2007, Blood.